Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Drops Registry Requirement In ICD Coverage Policy And Adds 'Shared Decision-Making'

Executive Summary

The new Medicare coverage policy for implantable cardioverter defibrillators, the first revision since 2005, incorporates MRI-compatible devices, tweaks some of the patient criteria, removes thenational registry requirement, and adds a new requirement for "shared decision-making" prior to implanting an ICD in certain patients so the patients understand their options.

You may also be interested in...



MRI And Cardiac-Rhythm Devices: A Match Made In Medicare

A proposed coverage policy from the US Centers for Medicare and Medicaid Services would not only cover magnetic resonance imaging for patients with an implanted cardiac rhythm management device with an FDA-approved indication for MRI-compatibility, but will also cover MRI in patients with devices without that FDA labeling in certain circumstances.

Medicare Agency Solicits Input On ICD Coverage For First Time Since 2005

The US Medicare agency opened a national coverage analysis to reconsider coverage indications for implantable cardioverter defibrillators and received input from 35 individuals, organizations, and companies during the initial public comment period. The agency did not specify any particular issues or deficiencies that it wants to address by updating its coverage policy, but CMS has not reconsidered the national coverage policy on ICDs since a major coverage expansion was implemented in 2005.

Boston Sci's Watchman Gets Positive Medicare Coverage Policy

CMS granted national coverage for left atrial appendage closure procedures to prevent stroke under more favorable conditions than what the Medicare agency had proposed in November. This is good news for Boston Scientific, which is ramping up marketing of its Watchman device.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122246

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel